3 Japanese AI Healthcare Stocks Trading Below Fair Value

Services and manufacturing activity are picking up across Europe and Asia, with inflation pressures easing and central banks signalling more flexibility. That mix often pulls attention toward growth themes that can scale as demand firms. Transformative AI healthcare stocks sit right in that spotlight, using data and algorithms to reshape treatment and research. This article highlights three stocks from the screener that show how this theme is playing out today.

The three stocks below are only a starting sample from this theme, and the full screen surfaced four more AI healthcare companies with equally compelling narratives that are not covered here. To identify your own highest conviction candidates in this space, go straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener and use it to filter and analyze the full set of stocks.

ASO International (TSE:9340)

ASO International is a Japan based specialist in dental orthodontics that designs and manufactures a wide range of treatment systems and devices, from clear aligners and lingual braces to 3D printers, AI driven scanning tools and digital modeling services for clinics. The company also offers tele consultation services under the AILINE brand and customized metal orthodontic parts that support complex cases. ASO International has a market cap of about ¥7.0b, which places it in the small cap bracket on the Tokyo Stock Exchange.

ASO International brings together clear aligners, lingual systems, in house 3D printing and AI powered scanning. This combination provides several ways to benefit as orthodontic practices adopt more digital workflows. Earnings have grown in the mid single digits recently, and forecasts point to faster profit growth ahead, supported by what are described as high quality earnings and solid margins. The stock currently trades at a P/E below industry averages and at a discount to one DCF estimate of future cash flows. This valuation profile could appeal to investors who focus on entry price. The main watchpoints are governance, including a board with no reported independent directors and limited refresh over recent years. That mix of growth potential, valuation characteristics and governance questions makes ASO International a company that some investors may consider examining more closely within the AI healthcare theme.

ASO International appears to be a small cap where solid margins and a relatively low P/E might be masking the real story. Get the full picture with the DCF valuation analysis for ASO International and see what the governance gap might really mean.

Build your own AI healthcare shortlist

ASO International and the two other AI healthcare stocks in this article all came from a single screener, but the real advantage is shaping your own set of filters. Use our flexible Screener to mix valuation, growth, quality and risk checks to suit your approach, or start with any of our curated Investing Ideas.

eWeLLLtd (TSE:5038)

eWeLLLtd runs a cloud platform that handles the nuts and bolts of home based medical care in Japan, from electronic medical records and insurance claims to staffing, training and AI supported nursing reports. The company generates all of its revenue, about ¥3.6b, from providing services to home visit nursing stations through products like iBow and related tools. eWeLLLtd currently has a market cap of roughly ¥32.1b, putting it firmly in the small to mid sized growth bracket on the Tokyo Stock Exchange.

eWeLLLtd stands out in the AI healthcare theme because it combines strong earnings growth with a focused niche in home nursing software, supported by a net margin above 30% and high return on equity. Analysts expect earnings and revenue to keep growing at rates well ahead of the broader Japanese market, while the current share price sits below one estimate of fair value based on future cash flows. At the same time, funding entirely through external borrowing and a board with relatively few independent directors introduce risk that careful investors will want to weigh. In addition, rising dividends and an ongoing buyback program mean eWeLLLtd is a stock where the next earnings updates could be especially important.

eWeLLLtd’s high margin growth story and home care niche could be only half the picture. Get the full context in the analyst forecasts for eWeLLLtd and see what the next phase might quietly hinge on.

FINDEX (TSE:3649)

FINDEX builds software and cloud services that help Japanese hospitals and clinics manage medical images, records, documents and referrals, along with AI assisted tools like CocktailAI for medical text generation and DigiWorker for workflow automation. Almost all revenue comes from the Medical Business at about ¥5.8b, with smaller contributions from the Public Sector Business at about ¥268 million and Health Tech Business at about ¥108 million, and all sales are currently generated in Japan. The stock has a market cap of roughly ¥20.3b, placing FINDEX firmly in the small cap bracket on the Tokyo Stock Exchange.

FINDEX offers focused exposure to digitising hospital workflows, with what appear to be high quality earnings, net margins above 20% and analyst forecasts that indicate double digit earnings growth. The stock also trades at a lower P/E than the wider Asian healthcare services group and at a discount to one estimate of fair value based on future cash flows, which can appeal if you care about entry price. At the same time, returns are currently being funded entirely with higher risk external borrowing and the board has a relatively low share of independent directors, so governance and balance sheet resilience are key issues to understand before forming a strong view.

FINDEX looks like a hospital software stock where high margins and a lower P/E might be masking the real story. See how the analysis report for FINDEX ties valuation, growth and funding risk together in one place.

Seeking Fresh Alternatives Beyond AI?

Fresh stock ideas can move quickly, and the most attractive entry points can appear before the broader market takes notice. Consider acting when opportunities align with your own research and objectives.

• Explore income opportunities with companies screened for sturdy payouts and balance sheets using the curated 47 dividend fortresses while current conditions meet your criteria.
• Identify early tech momentum by scanning the curated 56 AI infrastructure stocks while many of these picks may still be less widely followed and before any significant changes in pricing occur.
• Focus on resilience by reviewing the hand picked 53 resilient stocks with low risk scores list while market swings remain within your comfort range and pricing still reflects today’s risk views.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com